From the publishers of JADPRO

DLBCL Resource Center

Advertisement
FROM THE EDITOR

Welcome to the JADPRO Diffuse Large B-Cell Lymphoma Resource Center! We encourage you to take a look around at all the cutting-edge information, education, research, and other resources we’ve curated to empower your practice in this disease space. If you have any feedback or questions, please contact jadpro-editor@broadcastmed.com

Katherine L. Byar, MSN, APN, BC, BMTCN®️®️®️
Oncology/ Hematology Nurse Practitioner
Fred & Pamela Buffett Cancer Center
Nebraska Medicine
Omaha, Nebraska

News & Literature Highlights

2024 ASCO Annual Meeting Abstract

Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study

2024 ASCO Annual Meeting Abstract

Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study

2024 ASCO Annual Meeting Abstract

Subcutaneous epcoritamab (SC epcor) administered outpatient (outpt) for relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL): Results from phase 2 EPCORE NHL-6

OncLive

Glofitamab plus chemotherapy meets OS end point in R/R DLBCL

CPT: Pharmacometrics & Systems Pharmacology

Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

Cancer Diagnosis & Prognosis

Clinical outcomes in patients with DLBCL treated with R-CHOP according to radiotherapy and interim PET response

Haematologica

Efficacy of intravenous high-dose methotrexate in preventing relapse to the central nervous system in R-CHOP(-like)-treated, high-risk, diffuse large B-cell lymphoma patients and its effect on mortality: A systematic review and meta-analysis

Journal of Patient-Reported Outcomes

Are changes in patient-reported outcomes prognostic for diffuse large B-cell lymphoma survival? Results from the GOYA trial

HemaSphere

Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study

EJNMMI Research

Evaluation of therapeutic effect and prognostic value of 18F-FDG PET/CT in different treatment nodes of DLBCL patients

Advertisement
Advertisement